Gottlieb Stephen
Department of Cardiology, University of Maryland Medical Center, Baltimore, MD 21201, USA.
Postgrad Med. 2002 Dec;112(6 Suppl Heart):28-33. doi: 10.3810/pgm.12.2002.suppl24.128.
While beta-blockers have been demonstrated effective in many clinical trials of post-myocardial infarction patients, the trial populations have often excluded the elderly. Analysis of available data from older patients in large trials and results of smaller trials and retrospective studies suggest that benefit derived from beta-blocker therapy is not affected by age. Even though these data have limitations, beta-blocker therapy has been consistently associated with improved survival in all age groups, including patients older than 80 years. Underutilization of these drugs among the elderly is disconcerting given their benefit.
虽然β受体阻滞剂在心肌梗死后患者的许多临床试验中已被证明有效,但试验人群通常排除了老年人。对大型试验中老年患者的现有数据以及小型试验和回顾性研究结果的分析表明,β受体阻滞剂治疗带来的益处不受年龄影响。尽管这些数据存在局限性,但β受体阻滞剂治疗一直与所有年龄组(包括80岁以上患者)的生存率提高相关。鉴于其益处,老年人对这些药物的使用不足令人不安。